SIGA Technologies Sees Unusually Large Options Volume (NASDAQ:SIGA)

SIGA Technologies, Inc. (NASDAQ:SIGA) was the recipient of some unusual options trading activity on Wednesday. Stock traders purchased 1,200 call options on the company. This is an increase of approximately 1,438% compared to the typical daily volume of 78 call options.

Hedge Funds Weigh In On SIGA Technologies

A number of hedge funds have recently made changes to their positions in the company. Larson Financial Group LLC purchased a new stake in shares of SIGA Technologies during the third quarter worth approximately $30,000. DekaBank Deutsche Girozentrale acquired a new stake in SIGA Technologies during the 2nd quarter worth $40,000. EP Wealth Advisors LLC purchased a new stake in shares of SIGA Technologies during the third quarter worth $82,000. XTX Topco Ltd acquired a new stake in shares of SIGA Technologies in the third quarter valued at about $85,000. Finally, AQR Capital Management LLC purchased a new position in shares of SIGA Technologies in the second quarter worth about $99,000. Institutional investors and hedge funds own 55.40% of the company’s stock.

SIGA Technologies Stock Performance

Shares of NASDAQ SIGA opened at $6.06 on Friday. The firm has a market cap of $432.71 million, a PE ratio of 5.05 and a beta of 0.89. SIGA Technologies has a one year low of $4.26 and a one year high of $12.83. The firm has a fifty day moving average of $6.69 and a 200 day moving average of $7.68.

SIGA Technologies (NASDAQ:SIGA) last released its earnings results on Thursday, November 7th. The company reported $0.02 EPS for the quarter. The business had revenue of $10.01 million during the quarter. SIGA Technologies had a net margin of 49.33% and a return on equity of 49.06%. On average, equities analysts predict that SIGA Technologies will post 1.04 EPS for the current fiscal year.

SIGA Technologies Company Profile

SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.